API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
OM002 is a synthetic biology-produced human milk oligosaccharide (HMO) 2’-fucosyllactose, or 2’FL. The single most abundant HMO is 2’FL, which constitutes nearly 30% of the total HMO proportion in human milk.
Lead Product(s): 2-Fucosyllactose-Synthetic
Therapeutic Area: Gastroenterology Product Name: OM002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phoenix Biotech Acquisition Corp.
Deal Size: $136.0 million Upfront Cash: Undisclosed
Deal Type: Termination December 06, 2022
Details:
Anticipated cash resources will fund a Phase 2b clinical trial of Intrinsic’s lead, HMO-based drug candidate, OM002 (2’-fucosyllactose, or 2’FL), in over 400 patients with the constipation dominant form of irritable bowel syndrome (IBS-C).
Lead Product(s): 2-Fucosyllactose-Synthetic
Therapeutic Area: Gastroenterology Product Name: OM002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phoenix Biotech Acquisition Corp.
Deal Size: $136.0 million Upfront Cash: Undisclosed
Deal Type: Merger October 31, 2022